The immuno side of melanoma
16 Jul 2012
The immuno side of melanoma
Highlights of the 22nd EACR meeting and tackling glioblastoma
The changing field of drug development
Epigenetics of cancer and changes in DNA modification in tumours
Perifosine disappoints in refractory mCRC
Tivantinib first drug to have overall survival benefit as second-line hepatocellular carcinoma treatment
Young Voices United against CRC
Advances in radiotherapy for rectal cancer
Use of electronic data to raise the standard of cancer care
Addressing Asia’s high cancer incidence
The involvement of rare cancer patients in clinical research
Importance of early detection and the ‘Beyond the Shock’ programme